SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is seeing heightened activity and community discourse as investors debate its potential in the DePin sector amid ongoing speculation regarding major tech partnerships and future utility. While some users are actively accumulating during price consolidation, others remain skeptical, frequently labeling recent volatility as recurring pump-and-dump behavior.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics is currently trading at a deep discount, with its market capitalization falling below its total cash on hand, leading many in the community to argue that the market is essentially valuing its pipeline and proprietary TRACTr/ARM technology at zero. Investors are actively discussing the potential for an eventual rebound, a short squeeze, or an acquisition by a major pharmaceutical partner as the company navigates the market's overreaction to recent clinical data.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is trending as the community debates its potential for a massive breakout, with many speculating that its low market cap and historical volatility make it a prime candidate for a rapid pump during altcoin season. While some remain optimistic about future exchange listings and utility, others are actively trading the token as a high-risk scalp, often expressing frustration over price stagnation and perceived manipulative sell pressure.

Advanced Energy Industries, Inc. engages in the provision of power electronics conversion products. Its products include AC-DC power supply units, DC-DC conversion, high voltage amplifiers and power supplies, plasma power, controllers, sense, and measurement. The company was founded by Douglas S. Schatz in 1981 and is headquartered in Denver, CO.

Advanced Energy Industries Inc.

Advanced Energy Industries is trending due to the company's Q1 earnings report, which exceeded analyst expectations and demonstrated strong growth in its Data Center business. Investors are actively debating the sustainability of this AI-driven momentum, weighing the company's valuation against its role as a key supplier for critical data center infrastructure buildouts.

Green Plains, Inc. engages in the production of fuel-grade ethanol and corn oil, the provision of grain handling, and storage commodity marketing and distribution services. It operates through the Ethanol Production and Agribusiness and Energy Services segments. The Ethanol Production segment produces ethanol, distillers' grain, and corn oil at ethanol plants in Indiana, Iowa, Minnesota, Nebraska, Tennessee, and Texas. The Agribusiness and Energy Services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, renewable corn oil, natural gas, and other commodities. The company was founded in June 2004 and is headquartered in Omaha, NE.

Green Plains Inc

Green Plains is garnering attention as investors track its progress in carbon capture and operational efficiency, alongside ongoing discussions regarding its strategic focus on sustainable ingredients. The community remains closely engaged with the company's potential to benefit from government tax credits and broader biofuel policy shifts.

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Assembly Biosciences Inc

Assembly Biosciences is capturing investor attention due to intense speculation surrounding a potential buyout by its strategic partner, Gilead, following recent insider accumulation and positive preclinical data. The community remains focused on upcoming clinical catalysts for its antiviral pipeline, though sentiment is split between those bracing for volatility and others holding for a long-term revaluation.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF (FXI) is seeing heightened volatility and investor attention as market participants navigate a complex landscape of shifting trade relations with the U.S. and ongoing concerns regarding China's domestic economic stability. The community is actively debating the impact of recent geopolitical headlines, trade framework discussions, and potential stimulus measures on long-term growth versus the risks of structural economic hurdles.

American Exceptionalism Acquisition Corp. A is a blank check company. It was created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on July 11, 2025 and is headquartered in Menlo Park, CA.

American Exceptionalism Acquisition Corp. A - Ordinary Shares - Class A

American Exceptionalism Acquisition Corp. A

Investors are actively speculating on potential acquisition targets for AEXA, with community discourse centered on high-profile possibilities like Starlink, Anduril, and AI-focused tech firms. The stock is trending due to its status as a vehicle for Chamath Palihapitiya, drawing significant retail attention despite the lack of a formal announcement.

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

NeoGenomics is trending as investors react to strong Q1 earnings, which featured a revenue beat, high-margin NGS growth, and raised full-year guidance. The community is actively discussing the stock's potential for a long-term re-rate, driven by the rollout of the RaDaR ST assay and positive institutional analyst upgrades.

GDS Holdings Ltd. engages in developing and operating data centers in China. It builds, operates, and transfers data centers at other locations. Its data centers are carrier and cloud-neutral, which enable customers to connect to major telecommunications carriers, and to access a number of cloud service providers. The firm also offers colocation and managed services, which include direct private connection to major public cloud platforms. The company was founded by William Wei Huang in 2001 and is headquartered in Pudong, China.

GDS Holdings Limited - ADR

GDS Holdings

GDS Holdings is attracting investor attention as a major player in the Chinese AI infrastructure space, with the community closely monitoring its data center expansion and potential for long-term growth driven by rising demand for computing power. Recent discourse centers on its volatile price action, strategic capital management, and the broader impact of geopolitical developments on Chinese technology stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million for...

ACADIA Pharmaceuticals Q1 Earnings Call Highlights

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer's disease psychosis and trofinetide in Japan.

Chief Executive Officer Cath...

Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -54.23% and -5.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. Acadia delivered a solid first quarter of 2026 with total revenues of...

Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 3,506 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 3,506 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president directly owned...

James Kihara Sells 1,332 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $29,024.28. Following the completion of the sale, the...

ImmunityBio to Report Q1 Earnings: What's in the Cards?

IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.

IQVIA Set to Report Q1 Earnings: Here's What You Should Know

IQV heads into Q1 earnings release with steady growth expectations, driven by AI-backed solutions, strong bookings and rising pharma demand.

Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?

GRDN heads into Q1 earnings with revenues seen at $329.7M, as growth trends, vaccine volumes and IRA pricing impacts take center stage.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

ACAD
Acadia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ACAD News

ACADAcadia Pharmaceuticals Inc